Abstract
Cardiovascular disease still remains the leading cause of deaths worldwide. Atherosclerosis, the most common type of cardiovascular disease, has continued to progress due to many factors, genetics, and lifestyles. All cells require adequate adenosine triphosphate (ATP) levels to maintain their integrity and function. Myocardial ischemia commonly found in atherosclerosis can produce lower levels of ATP, which affects not only cellular energy, but also alters normal function. D-ribose, a naturally occurring pentose carbohydrate, has been shown to increase cellular energy levels and improve function following ischemia in pre-clinical studies and have demonstrated potential benefits in clinical evaluations. This review paper presents an overview of ischemic cardiovascular disease and the potential role that D-ribose could play in improving myocardial energy levels and function in the area of ischemic cardiovascular diseases.
Highlights
BackgroundCardiovascular disease still remains the leading cause of deaths worldwide for both men and women
In a separate study using a chronic in vivo canine model, Schneider et al found similar adenosine triphosphate (ATP) benefits with D-ribose supplementation and adenine supplementation following 20 minutes of global myocardial ischemia, as well as improvements in left ventricular diastolic dysfunction
Since preclinical animal studies have demonstrated that D-ribose supplementation enhanced the recovery of myocardial ATP levels and improved diastolic dysfunction following ischemia, Omran et al investigated the role of D-ribose supplementation in Class II-III ischemic, congestive heart failure patients
Summary
Cardiovascular disease still remains the leading cause of deaths worldwide for both men and women. In a separate study using a chronic in vivo canine model, Schneider et al found similar ATP benefits with D-ribose supplementation and adenine supplementation following 20 minutes of global myocardial ischemia, as well as improvements in left ventricular diastolic dysfunction Since preclinical animal studies have demonstrated that D-ribose supplementation enhanced the recovery of myocardial ATP levels and improved diastolic dysfunction following ischemia, Omran et al investigated the role of D-ribose supplementation in Class II-III ischemic, congestive heart failure patients. They found an improvement in diastolic dysfunction using echocardiographic parameters. Perkowski et al observed that the addition of D-ribose resulted in lower mortality and morbidities, along with a significant early postoperative improvement in cardiac index following revascularization [27]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
